Literature DB >> 18333858

Minimising harm: human variation and adverse drug reactions (ADRs).

J M Ritter1.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18333858      PMCID: PMC2291364          DOI: 10.1111/j.1365-2125.2008.03170.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Response to 'Communicating information about drug interactions'.

Authors:  David J Back; Sara E Gibbons
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

2.  Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework.

Authors:  Jean-Louis Prugnaud
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

3.  Foundation year 1 doctors and clinical pharmacology and therapeutics teaching. A retrospective view in light of experience.

Authors:  Mansour Tobaiqy; James McLay; Sarah Ross
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

4.  P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Authors:  Anneke Bierend; Thomas Rau; Renke Maas; Edzard Schwedhelm; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

5.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

6.  Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.

Authors:  Bharat Damle; Robert LaBadie; Penelope Crownover; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

7.  Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study.

Authors:  Ushma Mehta; David N Durrheim; Marc Blockman; Tamara Kredo; Ronald Gounden; Karen I Barnes
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

8.  Incidence of fatal adverse drug reactions: a population based study.

Authors:  Karin Wester; Anna K Jönsson; Olav Spigset; Henrik Druid; Staffan Hägg
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

9.  Perforated peptic ulcer and short-term mortality among tramadol users.

Authors:  Marie L Tørring; Anders Riis; Steffen Christensen; Reimar W Thomsen; Peter Jepsen; Jens Søndergaard; Henrik T Sørensen
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

10.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03
View more
  3 in total

Review 1.  Chairman of the Joint Formulary Committee, British National Formulary.

Authors:  Martin Kendall
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

2.  Drug regulation & therapeutic efficacy.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-06       Impact factor: 4.335

Review 3.  Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.

Authors:  Lateef Mohiuddin Khan
Journal:  Eur J Clin Pharmacol       Date:  2013-08-17       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.